Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 8/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.42 |
| ▸ | VEGFA | P15692 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9700936 | 0.81 | CCR8 (0.57) | CCR8KMT2A | |
| SCHEMBL4365693 | 0.80 | JAK2 (0.46) | PDE4APDE4BPDE4DPDE4CVEGFA | |
| SCHEMBL4369467 | 0.74 | PDE4B (0.53) | KMT2APDE4APDE4BPDE4DPDE4C | |
| SCHEMBL728672 | 0.73 | CYP19A1 (0.50) | KMT2APDE4APDE4BPDE4DPDE4C | |
| SCHEMBL730919 | 0.73 | CYP19A1 (0.50) | KMT2APDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7385897 | 0.73 | PDE4B (0.49) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL4366172 | 0.72 | PDE4B (0.51) | PDE4APDE4BPDE4DPDE4CVEGFA | |
| SCHEMBL19890539 | 0.71 | CCR8 (0.55) | CCR8KMT2A | |
| SCHEMBL7283419 | 0.71 | CCR8 (0.55) | CCR8KMT2A | |
| SCHEMBL30940174 | 0.71 | CCR8 (0.55) | CCR8KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2008006052-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | CCR8 298/4885KMT2A 3155/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.